Estimation of Second Cancer Risk in Patients Planned With Different Radiotherapy Regimes for Rectal Cancer - A Planning Study and Model-based Analysis
Sponsor study identifier
observational
25
1 country
1
Study Start
August 2015
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
November 2016
Actual (reported)Study Completion
November 2016
Actual (reported)Retrospective study comparing dose distribution of 3D conformal radiotherapy (3DCRT) and volumetric-modulated arc therapy (VMAT) to estimate secondary cancer risk for patients having had radiation therapy for rectal cancer. Twenty-five patients are included in this study. Planning CT scans are used for comparison of dose distribution and calculation of second cancer risk.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
November 2016
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
August 2015
Date type not reportedThis date has not been verified as actual or estimated.
October 4, 2015
Actual (reported)October 8, 2015
Actual (reported)November 2016
Actual (reported)November 2016
Actual (reported)Calculation of the organ-specific excess lifetime attributable risk (LAR) (%)
LAR is calculated for variable Ages at exposure
60 years (model-based calculation)
No Intervention in this retrospective Analysis. All patients included did receive Radiation therapy Independent of this study
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Patients having had radiation therapy for rectal cancer. Estimation of second cancer risk using data from planning CTs comparing dose Distribution using different Radiation therapy techniques (3DCRT vs VMAT).
Klinik Hirslanden, Institute for Radiotherapy
Zurich, CH-8032, Switzerland
Zwahlen DR, Bischoff LI, Gruber G, Sumila M, Schneider U. Estimation of second cancer risk after radiotherapy for rectal cancer: comparison of 3D conformal radiotherapy and volumetric modulated arc therapy using different high dose fractionation schemes. Radiat Oncol. 2016 Nov 10;11(1):149. doi: 10.1186/s13014-016-0723-6.
Daniel R Zwahlen, MD, MBA
Kantonsspital Graubünden
25 participants (actual enrollment reported by the registry).
First Submitted
October 4, 2015
First Posted
October 8, 2015
Study Start
August 2015
Date type not reportedThis date has not been verified as actual or estimated.
Aberrant DNA Methylation to Predict Metachronous Gastric Neoplasms
Contact the study team to confirm eligibility.
Primary Completion
November 2016
Actual (reported)Study Completion
November 2016
Actual (reported)Last Updated
December 13, 2016
Record last verified: 2016-12
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: